Tomahawk, WI 08/26/2014 (Basicsmedia) – AstraZeneca plc (ADR) (NYSE:AZN) shares continue to surge in the market after news emerged that Pfizer Inc. (NYSE:PFE) may table another takeover bid with the three-month ban period that prevented the same under U.K. Laws coming to a close according to CNBC’s correspondent, Catherine Boyle.

Pfizer Inc. (NYSE:PFE) initial bid of £69.4 billion was rejected three months ago, amidst parliamentary committees scrutinizing the effects of a potential merger, especially on its possible impact on the future of science and technology in Britain. Another concern at the moment is the fact that AstraZeneca management is the only one mandated to re-engage in private negotiations with Pfizer, and not the other way around. Another public offer can only be made’ after November 26; six months after the first takeover-bid was rejected.

“AstraZeneca can invite Pfizer Inc. (NYSE:PFE) to the table; the noises am hearing out of them suggest that’s pretty unlikely. Management seems pretty much determined to go alone,” said CNBC’s correspondent, Catherine Boyle

Pfizer is pursuing AstraZeneca plc (ADR) (NYSE:AZN) as one of the ways of escaping the huge tax regime in the U.S by setting its base in the U.K. in a process referred to as an inversion. Boyle believes it is unlikely that Pfizer will be successful this time around considering AstraZeneca remains confident of reporting favorable results with its new drugs in trials, in the coming months.

With a pipeline of new drugs that should have the ability of commanding impressive sales in the market, Boyle believes AstraZeneca may opt to go all the way alone as Pfizer may not add much value going forward. AstraZeneca plc (ADR) (NYSE:AZN), on the other hand, according to Boyle may only tolerate Pfizer advances if it comes with a much greater bid than the earlier rejected £69.4 billion.

“Pfizer Inc. (NYSE:PFE) can also make a private bid. […] That’s got to be one offer at some stage in the next three months and they will probably have to make pretty substantial much larger than their most recent £55 per share bid but it looks as though as Astra said last time it will need to be £59 per share,” said Boyle.

DISCLAIMER: This content is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.